+5 | The top 5 medtech stories for June 8, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. FDA releases May 2016 510(k) clearances The Food &Drug Administration released the 510(k) clearances it issued in May 2016. Read more 4. Google’s Verily Star Trek “Tricorder” moonshot flops Verily’s moonshot project which aimed to create a futuristic every-aspect diagnostic device and cancer treatment, much like Star Trek’s “Tricorder” devices, has flopped after 3 years in development. Read more 3. Medtronic teases new “extravascular” ICD system Medtronic today released results from feasibility studies of its new “extravascular” EV-ICD System implantable cardioverter defibrillator designed with leads placed outside the hearts and veins, under the rib cage. Read more 2. FDA clears Ares robot-assisted bronchoscopy device from Auris Surgical Robotics The FDA last month granted 510(k) clearance to the Ares robot-assisted bronchoscopy platform developed by stealthy Auris Surgical Robotics. Read more 1. Medtronic enters bundled ortho implant space with Responsive Orthopedics buy Medtronic (N...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Plus 5 Source Type: news

Related Links:

Legal costs surrounding Johnson and Johnson’s talc baby power and its blood thinner Xarleto bogged down the healthcare giant’s 1Q19 earnings. But while earnings from the New Brunswick, NJ-based company were down 14% from a year earlier, the firm managed to beat analyst expectations. J&J posted income of $3.75 billion or $1.39 per share for 1Q19. In 1Q18, the company brought in $4.37 billion or $1.60 per share. As a result, the healthcare company changed its full-year earnings forecast to a range of $8.53 to $8.63 a share, down from its previous estimate of between $8.50 and $8.65. The fi...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Katarina Rejlekova1, Maria C. Cursano2, Ugo De Giorgi3 and Michal Mego1* 12nd Department of Oncology, Faculty of Medicine, National Cancer Institute, Comenius University, Bratislava, Slovakia 2Oncology Unit, Università Campus Bio-Medico, Rome, Italy 3Medical Oncology Department, Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy Testicular germ cell tumors (TGCTs) represent the most common solid tumor in young men and is a model of curable cancer. The effectiveness of cisplatin-based chemotherapy secures more than 95% of patients' 5-years survival rate. Howeve...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Here, we report a case of advanced non ‐small‐cell lung cancer with a rare epidermal growth factor receptor (EGFR) exon 20 H773L/V774M compound mutation, which demonstrated poor clinical response to afatinib, a second‐generation EGFR‐TKI with pan‐human EGFR blocking activity. The anti‐cancer treatment was shifted to platinum‐ based chemotherapy, which resulted in a partial response. Uncommon mutations account for 10 –15% of epidermal growth factor receptor (EGFR) mutations in patients with non‐small‐cell lung cancer. Afatinib is currently the most efficient EGFR‐tyrosine kinase inhibitor (TKI) aga...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
Johnson &Johnson (NYSE:JNJ) said yesterday that its Ethicon biz completed its $3.4 billion acquisition of robotic surgery dev Auris Health and the $2.8 billion divestiture of its Advanced Sterilization Products to Fortive (NTSE:FTV). Redwood City, Calif.-based Auris Health, which was created by Intuitive Surgical (NSDQ:ISRG) founder and surgical robotics pioneer Dr. Fred Moll, developed and produces the robotic Monarch platform which has FDA clearance for diagnostic and therapeutic bronchoscopic procedures. The Monarch system features a controller interface for navigating the integrated flexible rob...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured Mergers & Acquisitions Robotics Sterilization / Calibration Wall Street Beat johnsonandjohnson Source Type: news
​Seventy-five percent of trauma injuries involve some kind of thoracic insult, a quarter of which need a procedural intervention like a chest tube. (Surg Clin North Am 2007;87[1]:95; Long-term illness, lung disease, and post-operative complications may cause pleural effusions or a pneumothorax, so treating these conditions quickly can significantly decrease patient morbidity and mortality. Other indications for chest tube placement include:Trauma: Pneumothorax, hemopneumothorax, or tension pneumothoraxLong-term illness: Pleural effusion (cancer, pneumonia)Infection: Empyema, purulent pleuriti...
Source: The Procedural Pause - Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays are widely used for complementary or companion diagnostic purposes during treatment with immune checkpoint inhibitors. However, limited information is available on the clinical reliability of the PD-L1 IHC assay using small biopsy samples. Participants included 46 patients with nonsmall cell lung cancer who underwent PD-L1 testing using 3 PD-L1 IHC assays (22C3, SP142, and SP263) for both small biopsy samples and surgical specimens from November 2017 to June 2018. The PD-L1 IHC assay results were analyzed with cut-off values of 1%, 5%, 10%, and 50%. The P...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Conclusion: We conclude that BTVA may have a future role in the treatment of lung cancer and should be investigated further in clinical trials.
Source: Journal of Bronchology and Interventional Pulmonology - Category: Respiratory Medicine Tags: Original Investigations Source Type: research
Conclusion VBN assisted EBUS-GS-TBLB for PPLs was an effective and safe procedure.
 DOI: 10.3779/j.issn.1009-3419.2019.03.01
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Conclusion Paraneoplastic limbic encephalitis is a rare paraneoplastic syndrome in nervous system caused by malignant neoplasms often characterized by facial neurological symptoms. The disease are usually associated with lung cancer (especially SCLC). Its nervous system symptoms occur earlier than the tumor diagnosis. Early diagnosis and treatment for primary tumors will increase the benefit. 
 DOI: 10.3779/j.issn.1009-3419.2019.03.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Condition:   Lung Cancer Interventions:   Procedure: Bronchoscopies;   Procedure: Sputum Sample;   Procedure: Venipuncture Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI);   Johnson&Johnson Pharmaceutical Research&Development, L.L.C. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Bronchoscopy | Cancer | Cancer & Oncology | Cardiology | Heart | Medical Devices | Orthopaedics | Study